Skip to main content

Table 1 Baseline characteristics stratified by sIgEtot group (low, intermediate, high)

From: Variability in total serum IgE over 1 year in severe asthmatics

Baseline characteristics (N = 41) Low IgE group (< 76 IU/mL) (N = 10) Intermediate IgE group (76–700 IU/mL) (N = 20) High IgE group (> 700 IU/mL) (N = 11) p value** Difference specification***
Age (years)
 Mean (± SD) 57.7 ± 15.7 49.5 ± 14.7 40.4 ± 13.4 0.03* 1 vs 3
Gender
 Male 5 (29%) 8 (47%) 4 (24%) 0.84  
 Female 5 (21%) 12 (50%) 7 (29%)   
Race
 Caucasian 10 (28%) 19 (53%) 7 (19%) 0.03* 1 vs 3; 2 vs 3
 Other 0 (0%) 1 (20%) 4 (80%)   
Smoking status
 Never smoked 6 (26%) 12 (52%) 5 (22%) 0.27  
 Former smoker 3 (25%) 7 (58%) 2 (17%)   
 Current smoker 1 (17%) 1 (17%) 4 (66%)   
BMI (kg/m2)
 < 30 9 (25%) 17 (47%) 10 (28%) 0.79  
 ≥ 30 1 (25%) 3 (75%) 0 (0%)   
Medical history
 Allergic rhinitis 2 (9%) 13 (56%) 8 (35%) 0.02* 1 vs 3; 1 vs 2
 Atopic dermatitis 3 (17%) 11 (61%) 4 (22%) 0.33  
 GERD 4 (44%) 4 (44%) 1 (11%) 0.23  
 Nasal polyps 2 (25%) 3 (38%) 3 (38%) 0.59  
Residence
 City 4 (18%) 10 (45%) 8 (36%) 0.51  
 Suburbs 4 (40%) 5 (50%) 1 (10%)   
 Rural/country 2 (22%) 5 (56%) 2 (22%)   
GINA level of asthma control
 Controlled 3 (21%) 8 (57%) 3 (21%) 0.39  
 Partly controlled 2 (18%) 7 (64%) 2 (18%)   
 Uncontrolled 5 (33%) 4 (27%) 6 (40%)   
Positive RAST testing
 D. pteronyssinus 4 (18%) 11 (50%) 7 (32%) 0.65  
 Grass mix 4 (22%) 6 (33%) 8 (44%) 0.07 2 vs 3
 Cat dander 2 (12%) 10 (59%) 5 (29%) 0.41  
 Dog dander 2 (12%) 7 (44%) 7 (44%) 0.16  
 Birch 0 (0%) 5 (42%) 7 (58%) 0.005* 1 vs 3; 2 vs 3; 2 vs 3
 Mold 1 (8%) 5 (42%) 6 (50%) 0.1  
Treatment
 ICS/LABA 10 (24%) 20 (49%) 11 (27%)  
 SABA 5 (18%) 18 (64%) 5 (18%) 0.02* 1 vs 2; 2 vs 3
 LTRA 2 (10%) 12 (60%) 6 (30%) 0.11  
 OCS 1 (13%) 3 (37%) 4 (50%) 0.34  
 SABA/SAAC 1 (33%) 1 (33%) 1 (33%) 1  
 LABA 0 (0%) 1 (100%) 0 (0%) 1  
Asthma status
 % Predicted FEV1—mean (SD) 72.3 ± 28.6 86.6 ± 18.6 80.2 ± 12.2 0.20  
 ACQ total score—median (range) 12.0 (2.0–14.0) 8.0 (5.0–13.0) 8.0 (4.0–13.0) 0.77  
 Exhaled nitric oxide—median (range) 15.6 (7.1–46.7) 20.8 (9.6–154.0) 120.9 (5.7–236.0) 0.82  
  1. BMI, Body Mass Index; D. pteronyssinus, Dermatophagoides pteronyssinus; FEV1, forced expiratory volume in 1 s; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroids; ICS/LABA, inhaled corticosteroids/long-acting β2 agonists; LABA, long-acting β2 agonists; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroids; RAST, radio-allergo sorbent test; SD, standard deviation; SABA, short-acting β2 agonists; SABA/SAAC, short-acting anticholinergic
  2. * p-value < 0.05 were considered statistically significant; ** Regression analysis for age/Fisher’s exact for other (categorical) variables; *** Tukey test for age/general linear model with contrasts for other (categorical) variables, the column indicates between which groups were observed the statistical differences: 1 = low sIgEtot subgroup, 2 = intermediate sIgEtot subgroup and 3 = high sIgEtot subgroup